Weekly Digest – May 2025 Weekly Digest – May 2025 1 May 2025: OBI Pharma announces U.S. FDA clearance of IND application for a Phase 1/2 study of OBI-902, a Trop-2 targeting ADC OBI Pharma received U.S. FDA clearance to […]
Weekly Digest – May 2025 Weekly Digest – May 2025 1 May 2025: The NMPA has granted breakthrough-therapy-designated drug for B7-H4-targeted antibody-drug conjugate HS-20089 Hansoh Pharmaceuticals B7-H4-targeted ADC, HS-20089, has been granted BTD by China’s National Medical Products Administration (NMPA) […]
Weekly Digest – May 2025 Weekly Digest – May 2025 28 Apr 2025: Orum Therapeutics provides program update and announces drug candidate nomination Orum Therapeutics has discontinued the clinical development of ORM-5029, its HER2-targeted degrader-antibody conjugate (DAC), following an internal […]
Weekly Digest – May 2025 Weekly Digest – May 2025 29 Apr 2025: Araris Biotech AG announces research agreement to develop next-generation ADCs using Araris’ AraLinQ technology Araris Biotech has signed a research agreement with Johnson & Johnson to develop […]
Weekly Digest – May 2025 Weekly Digest – May 2025 2 May 2025: DCx accelerates multi-modal ADC development DCx Biotherapeutics has launched with a focus on developing multi-modal antibody-drug conjugates (MM-ADCs) targeting genetically-defined cancers The company in-licensed Repare Therapeutics’ SNIPRx, […]
Weekly Digest – May 2025 Weekly Digest – May 2025 25 Apr 2025: Chinese biotech inks ADC platform deal with ConjugateBio Escugen has signed an exclusive option agreement with ConjugateBio to license its EZWi-Fit platform for next-generation antibody-drug conjugates (ADCs) […]
